Polyrizon Ltd. PLRZ
Set alert
10.75 USD +1.75 +19.40%
At close · Oct 30
10.54 -0.21 -1.95%
After hours · Oct 30, 4:00 PM ET
9.44 Day range 10.86
3.13 52-week range 17.17
- YTD
- +26.62%
- 1 year
- +73.95%
- Open
- 9.46
- Prev close
- 9.00
- Mkt cap
- 26.11M
- Vol
- 46.22K
- Avg vol
- 53.59K
- EPS
- -4.97
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.44
- High
- 10.86
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.08
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.17
- 200-d avg
- 1.17
- 1y target
- 0.00
MAX chart
Events in this range
- Nov 28, 2025Split: 1 for 6
Signals (29)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 2026 | 2 days ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| SMA: Bullish | Jul 20, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | Apr 20, 2026 | 6 months ago |
| SMA: Bearish | Mar 23, 2026 | 7 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Dec 1, 2025 | 11 months ago |
| SMA: Bearish | Oct 13, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| SMA: Bullish | Sep 8, 2025 | 1 year ago |
| SMA: Bearish | Sep 1, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 7, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
Key statistics
- Market cap
- 6.79M
- Enterprise value
- 5.46M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -0.24
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 23.00K
- Total debt
- 151.00K
- Return on equity
- 0.00%
- Shares outstanding
- 4.19M
- Short % of float
- 0.00%
- 50-day average
- 1.17
- 200-day average
- 1.17
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
PLRZ Revenue — annual 0
PLRZ Net income — annual -3.33M
PLRZ EPS — annual -4.90
About Polyrizon Ltd.
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a containment barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- polyrizon-biotech.com
News
- Polyrizon Completes Participant Enrollment In Its Trial Of NASARIX To Treat Airborne Allergens
- Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Polyrizon Files New US Divisional Patent Application With USPTO, Further Expanding Its IP Portfolio Relating To Proprietary Mucoadhesive Technology
- Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
- Polyrizon Enrolls First Patient In U.S. NASARIX Allergy Blocker Trial, Entering Clinical Stage
- Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
- Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
Your note
Sign in to keep a note on PLRZ — it syncs with the Stock Master app.